Pharvaris (PHVS) Cash & Equivalents Growth (1y) (2020 - 2026)
Powered by 
Analysis
Pharvaris (PHVS) Cash & Equivalents Growth (1y) (2020 - 2026) Analysis & Trends
Peer Set
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Cash & Equiv. Growth (1y) (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 138.74 Bn | 130.89 Bn | 2.84 Bn | 23.56% |
| 2 | Regeneron Pharmaceuticals | 85.52 Bn | 77.52 Bn | 3.93 Bn | 23.05% |
| 3 | Argenx Se | 63.51 Bn | 58.32 Bn | 1.37 Bn | 71.81% |
| 4 | Moderna | 58.04 Bn | 52.91 Bn | 52.00 Mn | 34.71% |
| 5 | Revolution Medicines | 44.06 Bn | 44.06 Bn | - | - |
| 6 | BeOne Medicines | 39.98 Bn | 34.88 Bn | 1.53 Bn | 84.98% |
| 7 | Alnylam Pharmaceuticals | 35.46 Bn | 32.15 Bn | 992.69 Mn | 53.39% |
| 8 | Royalty Pharma | 28.41 Bn | 27.57 Bn | - | 28.50% |
| 9 | Insmed | 27.44 Bn | 26.28 Bn | 358.27 Mn | -57.58% |
| 10 | Pharvaris | 2.14 Bn | 1.77 Bn | 85,072.10 | 63.77% |
Historic Data
Download Data
Historic Data
| Date | Value |
|---|---|
| Jun 30, 2026 | 63.77% |
| Mar 31, 2026 | 116,223,395.77% |
| Dec 31, 2025 | 13.18% |
| Sep 30, 2025 | 14.85% |
| Jun 30, 2025 | -38.94% |
| Mar 31, 2025 | -37.83% |
| Dec 31, 2024 | -28.73% |
| Sep 30, 2024 | 94.43% |
| Jun 30, 2024 | 89.62% |
| Mar 31, 2024 | 175.79% |
| Dec 31, 2023 | 154.94% |
| Sep 30, 2023 | -13.53% |
| Jun 30, 2023 | -9.20% |
| Mar 31, 2023 | -33.63% |
| Dec 31, 2022 | -31.06% |
| Sep 30, 2022 | -22.66% |
| Jun 30, 2022 | -20.45% |
| Mar 31, 2022 | -23.96% |
| Dec 31, 2021 | 103.66% |
| Dec 31, 2020 | 422.66% |